Showing 20 of 81 recruiting trials for “malt-lymphoma”
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
👨⚕️ Laura S Samples, M.D., National Heart, Lung, and Blood Institute (NHLBI)📍 1 site📅 Started Mar 2026View details ↗
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RecruitingNCT07356882 ↗
European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma
👨⚕️ Mathieu SIMONIN, MD, Assistance Publique - Hôpitaux de Paris📍 1 site📅 Started Nov 2025View details ↗
Mosunetuzumab for CLL MRD Clearance
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Enrolling by InvitationNCT07173790 ↗
Watch and Wait or Worry and Wait in Indolent Lymphoma
👨⚕️ Ja Min Byun, MD, PhD, Seoul National University Hospital📍 4 sites📅 Started Oct 2025View details ↗
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
👨⚕️ Study Director, Dizal (Jiangsu) Pharmaceutical Co., Ltd.📍 2 sites📅 Started Sep 2025View details ↗
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
👨⚕️ Mazyar Shadman, MD, MPH, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Jun 2025View details ↗
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RecruitingNCT06784167 ↗
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
64Cu-LLP2A for Imaging Hematologic Malignancies
👨⚕️ Farrokh Dehdashti, M.D., Washington University School of Medicine📍 1 site📅 Started Feb 2025View details ↗
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RecruitingNCT06788639 ↗
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
RecruitingNCT06821880 ↗
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
Page 1 of 5Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →